259860-08-7

Basic information

• Product Name: 6-Bromo-5-fluoroindole
• Synonyms: 6-Bromo-5-fluoroindole;6-bromo-5-fluoro-1H-indole;1H-Indole, 6-broMo-5-fluoro-
• CAS NO: 259860-08-7
• Molecular Formula: C₈H₅BrFN
• Molecular Weight: 214.04
• EINECS: 1592732-453-0
• Product Categories: Boronic Acid;Heterocyclic Compounds;Halogenated Heterocycles;Heterocyclic Building Blocks;Indoles;IndolesBuilding Blocks
• Mol File: 259860-08-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 82-84 °C
• Boiling Point: 315.908°C at 760 mmHg
• Flash Point: 144.856°C
• Appearance: /
• Density: 1.750
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.68
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 15.23±0.30(Predicted)
• CAS DataBase Reference: 6-Bromo-5-fluoroindole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-5-fluoroindole(259860-08-7)
• EPA Substance Registry System: 6-Bromo-5-fluoroindole(259860-08-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 259860-08-7(Hazardous Substances Data)

Usage

General Description

6-Bromo-5-fluoroindole is a chemical compound that belongs to the class of heterocyclic indole compounds. It is a derivative of indole with bromine and fluorine substituents. 6-Bromo-5-fluoroindole has a molecular formula C8H5BrFNO and a molecular weight of 217.039 g/mol. It is commonly used as a building block for the synthesis of pharmaceutical and biologically active compounds, such as potential drug candidates for the treatment of various diseases. 6-Bromo-5-fluoroindole is known for its diverse applications in medicinal chemistry and drug discovery. Its unique structural features make it a valuable starting material in the development of novel therapeutic agents.

InChI:InChI=1/C8H5BrFN/c9-6-4-8-5(1-2-11-8)3-7(6)10/h1-4,11H

Upstream product

• 259860-00-9 2-fluoro-4-methyl-5-nitro-phenylamine 
• 224185-19-7 3-bromo-4-fluoro-6-methylnitrobenzene 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1034894-73-9 [2-(4-bromo-5-fluoro-2-nitro-phenyl)-vinyl]-dimethyl-amine 

Downstream Products

• 1211593-30-4 6-bromo-5-fluoro-1H-indole-3-carbonitrile 
• 1403898-91-8 5-fluoro-6-phenyl-1H-indole 
• 1403898-90-7 5-fluoro-6-phenyl-2,3-dihydro-1H-indole 

Relevant articles and documents

REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS

The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

SUBSTITUTED QUINOXALINE DERIVATIVES

The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.

Substituted indoles as alpha-1 agonists

This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: wherein m, A, X, Y, R1, R2, R3, R4 and R5 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.